Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease.
Clin Pharmacol Ther
; 53(6): 691-5, 1993 Jun.
Article
en En
| MEDLINE
| ID: mdl-8513661
ABSTRACT
OBJECTIVE:
To assess the value of serum measurements of tacrine hydrochloride and its metabolite in predicting risk of adverse reaction in Alzheimer's disease.METHODS:
The study was an outpatient-based controlled clinical trial. Study subjects were 35 female and 31 male patients who were receiving 50 to 150 mg tacrine hydrochloride per day.RESULTS:
Serum concentration of tacrine hydrochloride and ratio of tacrine hydrochloride to metabolite were significantly higher in the 45 patients with symptomatic adverse effects (p < 0.001). The tacrine hydrochloride to metabolite ratio was significantly higher (p < 0.05) in the 30 patients in whom abnormal liver function developed, but concentration of tacrine hydrochloride was not significantly higher. Women showed a higher incidence of adverse effects (p < 0.05), and tacrine hydrochloride concentrations were higher (p < 0.05). Tacrine hydrochloride concentration and tacrine hydrochloride to metabolite ratio were higher in both men and women in whom adverse effects developed.CONCLUSION:
Tacrine hydrochloride concentration is valuable in predicting the development of adverse effects, and its measurement may improve the use of the drug.
Buscar en Google
Banco de datos:
MEDLINE
Asunto principal:
Tacrina
/
Enfermedad de Alzheimer
Tipo de estudio:
Clinical_trials
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Clin Pharmacol Ther
Año:
1993
Tipo del documento:
Article
País de afiliación:
Reino Unido